Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Elite Pharmaceuticals INC /NV/ (NASDAQ:ELTP) Executive Vice President of Operations, Douglas Plassche, sold 200,000 in Stock Options (right to buy) at a price of $0.579, for a total value of $115799, according to a Form 4 filing with the Securities and Exchange Commission.
The transaction, which occurred on July 8, 2025, was disclosed in a Form 4 filing made public on July 10, 2025. Following the sale, Plassche directly owns 2,300,000 shares of Elite Pharmaceuticals INC /NV/. The company maintains strong financial health with a current ratio of 4.88, indicating robust liquidity. Discover more insights and 10 additional ProTips about ELTP with an InvestingPro subscription, including detailed Fair Value analysis and comprehensive financial metrics.
In other recent news, Elite Pharmaceuticals reported a robust 52% increase in total revenues for Q1 2025, reaching $84 million. Operating income also saw a significant rise of 82%, totaling $19.6 million. The company launched a generic version of Vyvanse, capturing an 8-10% market share despite competition from 13 other companies. Additionally, Elite Pharmaceuticals is considering potential Nasdaq uplisting and international expansion, underscoring its strategic growth initiatives. The company is actively evaluating mergers and acquisitions as part of its future plans. Elite Pharmaceuticals’ performance reflects its focus on expanding its generic drug portfolio, with ongoing efforts to file additional Abbreviated New Drug Applications (ANDAs). Despite these positive developments, the stock price experienced a decline post-earnings, suggesting potential investor concerns. Analyst feedback was not provided in the recent reports, leaving market responses open to interpretation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.